794 related articles for article (PubMed ID: 20100965)
1. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Silver DP; Richardson AL; Eklund AC; Wang ZC; Szallasi Z; Li Q; Juul N; Leong CO; Calogrias D; Buraimoh A; Fatima A; Gelman RS; Ryan PD; Tung NM; De Nicolo A; Ganesan S; Miron A; Colin C; Sgroi DC; Ellisen LW; Winer EP; Garber JE
J Clin Oncol; 2010 Mar; 28(7):1145-53. PubMed ID: 20100965
[TBL] [Abstract][Full Text] [Related]
2. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
Curigliano G; Goldhirsch A
J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
Lee E; McKean-Cowdin R; Ma H; Spicer DV; Van Den Berg D; Bernstein L; Ursin G
J Clin Oncol; 2011 Nov; 29(33):4373-80. PubMed ID: 22010008
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer: disease entity or title of convenience?
Carey L; Winer E; Viale G; Cameron D; Gianni L
Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
[TBL] [Abstract][Full Text] [Related]
5. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
[TBL] [Abstract][Full Text] [Related]
6. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.
Byrski T; Dent R; Blecharz P; Foszczynska-Kloda M; Gronwald J; Huzarski T; Cybulski C; Marczyk E; Chrzan R; Eisen A; Lubinski J; Narod SA
Breast Cancer Res; 2012 Jul; 14(4):R110. PubMed ID: 22817698
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and treatment strategy for triple-negative breast cancer.
Yamamoto Y; Iwase H
Int J Clin Oncol; 2010 Aug; 15(4):341-51. PubMed ID: 20632057
[TBL] [Abstract][Full Text] [Related]
8. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R
Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for triple-negative breast cancers with defective homologous recombination.
Jaspers JE; Rottenberg S; Jonkers J
Biochim Biophys Acta; 2009 Dec; 1796(2):266-80. PubMed ID: 19616605
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
[TBL] [Abstract][Full Text] [Related]
11. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
12. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
[TBL] [Abstract][Full Text] [Related]
13. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.
Holánek M; Bílek O; Nenutil R; Kazda T; Selingerová I; Zvaríková M; Palácová M; Krásenská M; Vyzula R; Petráková K
Klin Onkol; 2019; 32(Supplementum2):31-35. PubMed ID: 31409079
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
Lips EH; Mulder L; Oonk A; van der Kolk LE; Hogervorst FB; Imholz AL; Wesseling J; Rodenhuis S; Nederlof PM
Br J Cancer; 2013 May; 108(10):2172-7. PubMed ID: 23558900
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
17. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
18. Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.
Musolino A; Michiara M; Bella MA; Naldi N; Zanelli P; Bortesi B; Capelletti M; Soldani L; Camisa R; Martella E; Franciosi V; Savi M; Neri TM; Ardizzoni A; Cascinu S
Tumori; 2005; 91(6):505-12. PubMed ID: 16457150
[TBL] [Abstract][Full Text] [Related]
19. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
[TBL] [Abstract][Full Text] [Related]
20. Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
Li M; Zhang J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Gene; 2016 Jun; 584(1):26-30. PubMed ID: 26956035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
